|
Arthritis, Psoriatic
|
0.400 |
Biomarker
|
disease |
BEFREE |
With the emergence of tumor necrosis factor inhibitors (TNFi), therapeutic outcomes in PsA have improved substantially.
|
28490202 |
2017 |
|
Arthritis, Psoriatic
|
0.400 |
Biomarker
|
disease |
BEFREE |
While the previously reported association between TNF*-238A and psoriasis seems to primarily reflect LD with PSORS1, TNF*-857T may represent a risk factor for PsA that is independent of the PSORS1 allele.
|
17530646 |
2007 |
|
Arthritis, Psoriatic
|
0.400 |
Biomarker
|
disease |
BEFREE |
We used data from two pivotal trials of tumour necrosis factor (TNF) inhibitors in PsA (IMPACT II and GO-REVEAL) and identified patients in DAPSA remission (REM, ≤4), and low, moderate or high disease activity (LDA, ≤14; MDA, ≤28; HDA, >28) at 6 months.
|
27457512 |
2017 |
|
Arthritis, Psoriatic
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We investigated the role of single-nucleotide polymorphisms (SNPs) at positions -238, -308, and +489 of the TNF-α gene in the genetic susceptibility to PsA, in the severity of the disease, and, finally, in the response to TNF-α inhibitors (adalimumab, etanercept, or infliximab).
|
24594669 |
2014 |
|
Arthritis, Psoriatic
|
0.400 |
Biomarker
|
disease |
BEFREE |
We evaluated tofacitinib in patients with active psoriatic arthritis who had previously had an inadequate response to tumor necrosis factor (TNF) inhibitors.
|
29045207 |
2017 |
|
Arthritis, Psoriatic
|
0.400 |
Biomarker
|
disease |
BEFREE |
We determined the expression of ILT4 and analysed the relationship with the expression of costimulatory proteins and tumor necrosis factor-α (TNF-α) production in monocytes from patients with psoriatic arthritis (PsA) starting anti-TNF treatment.
|
24676037 |
2014 |
|
Arthritis, Psoriatic
|
0.400 |
Biomarker
|
disease |
BEFREE |
We also explore the role of MTX in combination therapy with tumor necrosis factor inhibitors, in addition to its safety and tolerability, to answer the question: should methotrexate have any place in the treatment of psoriatic arthritis?
|
31277747 |
2019 |
|
Arthritis, Psoriatic
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We aimed to characterize the PsA genotype by gene expression profile and to research the effect in gene modulation of methotrexate (MTX) and TNF-inhibitors (TNF-I) in PsA-treated patients.
|
25339124 |
2014 |
|
Arthritis, Psoriatic
|
0.400 |
Biomarker
|
disease |
BEFREE |
Twenty (20) of the PA patients were also tested for the ability of their stimulated cells to secrete Interleukin-1 (IL-1 beta) and tumor necrosis factor (TNF alpha).
|
9548075 |
1998 |
|
Arthritis, Psoriatic
|
0.400 |
Biomarker
|
disease |
BEFREE |
Trajectory of radiographic change over a decade: the effect of transition from conventional synthetic disease-modifying antirheumatic drugs to anti-tumour necrosis factor in patients with psoriatic arthritis.
|
30247726 |
2019 |
|
Arthritis, Psoriatic
|
0.400 |
Biomarker
|
disease |
BEFREE |
To investigate the levels of the proinflammatory cytokines tumor necrosis factor α (TNF-α), interleukin 23 (IL-23) and IL-17 in patients with psoriasis and psoriatic arthritis with concomitant metabolic syndrome.
|
30858782 |
2019 |
|
Arthritis, Psoriatic
|
0.400 |
Biomarker
|
disease |
BEFREE |
To identify (1) whether tumor necrosis factor inhibitor (TNFi) drug levels/anti-drug antibodies (ADAb) are associated with treatment response and disability in patients with psoriatic arthritis (PsA); and (2) the factors associated with TNFi drug levels.
|
31371650 |
2019 |
|
Arthritis, Psoriatic
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
To examine whether initiation of interleukin (IL)-17, IL-12/23 or tumour necrosis factor (TNF) inhibitor is associated with an increased risk of serious infection among real-world psoriasis (PsO) or psoriatic arthritis (PsA) patients.
|
31672774 |
2020 |
|
Arthritis, Psoriatic
|
0.400 |
Biomarker
|
disease |
BEFREE |
To examine treatment patterns and therapy modifications in U.S. patients with PsA receiving a tumor necrosis factor inhibitor (TNFi) or an anti-interleukin (IL)-12/23 inhibitor.
|
29952704 |
2018 |
|
Arthritis, Psoriatic
|
0.400 |
Biomarker
|
disease |
BEFREE |
To examine treatment patterns and therapy modifications in U.S. patients with PsA receiving a tumor necrosis factor inhibitor (TNFi) or an anti-interleukin (IL)-12/23 inhibitor.
|
29557701 |
2018 |
|
Arthritis, Psoriatic
|
0.400 |
Biomarker
|
disease |
BEFREE |
To evaluate the risk of AF and major adverse cardiovascular events (MACE) associated with use of ustekinumab vs tumor necrosis factor inhibitors (TNFi) in patients with psoriasis or psoriatic arthritis.
|
30916734 |
2019 |
|
Arthritis, Psoriatic
|
0.400 |
Biomarker
|
disease |
BEFREE |
To evaluate the 8-year survival of the first tumor necrosis factor inhibitor (TNFi) in patients with axial spondyloarthritis (SpA) or psoriatic arthritis (PsA), identify the predictive factors for withdrawal, and compare the discontinuation rates for infliximab, etanercept, and adalimumab.
|
27696735 |
2017 |
|
Arthritis, Psoriatic
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
To determine whether polymorphisms in Fcgamma receptor type IIIA (FcgammaRIIIA) correlate with clinical efficacy in patients with rheumatoid arthritis (RA) and patients with psoriatic arthritis (PsA) being treated with tumor necrosis factor alpha (TNFalpha) inhibitors.
|
16142749 |
2005 |
|
Arthritis, Psoriatic
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
To describe the use of tumor necrosis factor-alpha inhibitors (TNFis) among pregnancies ending in a live birth and with a diagnosis of ankylosing spondylitis (AS), Crohn's disease (CD), juvenile idiopathic arthritis (JIA), psoriasis (PsO), psoriatic arthritis (PsA), rheumatoid arthritis (RA), or ulcerative colitis (UC).
|
30430682 |
2019 |
|
Arthritis, Psoriatic
|
0.400 |
Biomarker
|
disease |
BEFREE |
To analyse clinical, serological and sonographic differences between rheumatoid arthritis (RA) and polyarticular psoriatic arthritis (PsA) patients on anti-TNF therapy in clinical remission.
|
27749227 |
2017 |
|
Arthritis, Psoriatic
|
0.400 |
Biomarker
|
disease |
BEFREE |
This study assessed the use of scintigraphy and magnetic resonance imaging (MRI) in identifying the presence and amount of tumour necrosis factor-α (TNF-α) in the joint or skin of patients with psoriatic arthritis, to guide the course of treatment more efficiently.
|
27937056 |
2017 |
|
Arthritis, Psoriatic
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
This study aims to evaluate the drug survival and effectiveness of ustekinumab in psoriatic arthritis (PsA) patients naïve to biologics or inadequate responders to tumor necrosis factor (TNF-IR) inhibitors in real life.
|
29411182 |
2018 |
|
Arthritis, Psoriatic
|
0.400 |
Biomarker
|
disease |
BEFREE |
This retrospective study aimed to evaluate the long-term efficacy and effects on lipid profile and Atherogenic Index of antitumor necrosis factor (TNF)α therapy with adalimumab in patients with moderate-to-severe psoriasis or psoriatic arthritis.
|
29564871 |
2018 |
|
Arthritis, Psoriatic
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
This group also had higher peripheral disease activity (imaging only vs clinical AxPsA: mean (SD) tender joint count 5.3 (6.1) vs 3.3 (4.7), swollen joint count 1.9 (2.9) vs 1.2 (2.4); p < 0.001 for both comparisons) and was less often treated using TNF inhibitors (16.1 vs 38.2%; p < 0.001) than patients who were classified as axPsA.
|
29948352 |
2018 |
|
Arthritis, Psoriatic
|
0.400 |
Biomarker
|
disease |
BEFREE |
These drugs block TNFα from interacting with its receptors and have enabled the development of breakthrough therapies for the treatment of several autoimmune inflammatory diseases, including rheumatoid arthritis, Crohn's disease, and psoriatic arthritis.
|
29518978 |
2018 |